Company intelligence / Profile preview
Vigeo Therapeutics
Cambridge, Massachusetts, United Statesvigeotx.com ↗
- Ownership
- Private
- Employees
- ~12
- Development stage
- Phase 2
01
Overview
Vigeo’s lead program VT1021 has shown promising results in recurrent glioblastoma, with a Phase 1/2 study reporting complete responses in some patients and a disease control rate of 50%. The company is enrolling patients in a Phase 3 registration-ready trial as part of the AGILE Study. Preclinical work is ongoing for neurodegenerative and inflammatory indications. VT1021 increases endogenous TSP‑1 levels, reprogramming the tumor microenvironment to be less immunosuppressive and more tumor-inhibiting. Notably, high expression of both CD36 and CD47 correlates with better response to therapy.
- Therapeutic areas
- GastroenterologyOncologyNeurology
- Modalities
- Peptides (specifically small peptides derived from prosaposin/PSAP)Small moleculeBiologic
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Morningside Venture Investments, Ltd. provides financing support; no major pharma partnerships disclosed.
Beyond the preview
Go deeper on Vigeo Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vigeo Therapeutics.